2023
HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis
Mezzacappa C, Mahmud N, Serper M, John B, Taddei T, Kaplan D. HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis. Hepatology Communications 2023, 7: e0344. PMID: 38055642, PMCID: PMC10984661, DOI: 10.1097/hc9.0000000000000344.Peer-Reviewed Original ResearchRate of HCCBlood glucose controlBG controlIncident HCCGlucose controlCox proportional hazards regressionEtiology of cirrhosisProportional hazards regressionUnited States veteransHemoglobin A1c measurementsCirrhosis careHgb A1cHCC ratesHazards regressionNational cohortHCC riskA1c measurementStates veteransCirrhosisHigh riskDiabetesSustained controlHCCControl stateCohortLiver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis
John B, Dang Y, Kaplan D, Jou J, Taddei T, Spector S, Martin P, Bastaich D, Chao H, Dahman B. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis. Clinical Gastroenterology And Hepatology 2023, 22: 778-788.e7. PMID: 38061410, PMCID: PMC10960676, DOI: 10.1016/j.cgh.2023.11.020.Peer-Reviewed Original ResearchSustained virological responseLiver stiffness measurementHepatitis C virusHepatocellular carcinomaHCV cirrhosisDiabetes mellitusAnnual riskChronic hepatitis C virusPortal hypertension-related complicationsRate of HCCRisk of HCCHypertension-related complicationsRetrospective cohort studyVeterans Health AdministrationStiffness measurementHCV eradicationVirological responseCohort studyC virusHCC riskLower riskCirrhosisCutoff levelHealth AdministrationAbstractTextThe Association Between Homelessness and Key Liver-Related Outcomes in Veterans With Cirrhosis
Pulaski M, Bittermann T, Taddei T, Kaplan D, Mahmud N. The Association Between Homelessness and Key Liver-Related Outcomes in Veterans With Cirrhosis. The American Journal Of Gastroenterology 2023, 119: 297-305. PMID: 37782293, DOI: 10.14309/ajg.0000000000002535.Peer-Reviewed Original ResearchInverse probability treatmentCause mortalityCohort studyCox regressionHepatocellular carcinomaProbability treatmentVeterans Health Administration patientsLiver-related outcomesTime-updated variablesLiver-related mortalityRetrospective cohort studyCause-specific mortality analysesVeterans Health AdministrationRisk regression modelsCirrhosis decompensationCirrhosis diagnosisPatient outcomesPatientsHomeless patientsHealth AdministrationMortality analysisCirrhosisMortalityDrivers of mortalityDecompensationRefractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites
Chin A, Bastaich D, Dahman B, Kaplan D, Taddei T, John B. Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites. Hepatology 2023, 79: 844-856. PMID: 37625139, DOI: 10.1097/hep.0000000000000577.Peer-Reviewed Original ResearchLiver-related deathRefractory hepatic hydrothoraxRefractory ascitesMELD-NaHepatic hydrothoraxHigh riskRetrospective cohort studyRA overallSecond paracentesisCohort studyPrimary outcomeSerious complicationsEligibility criteriaCirrhosisInadequate evidenceParacentesisHydrothoraxAscitesDeathPatientsTransplantationRiskMortalityParticipantsComplicationsThe role of routine biopsy of the background liver in the management of hepatocellular carcinoma
Lee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.Peer-Reviewed Original ResearchConceptsLiver biopsyEarly HCC stagesHepatocellular carcinoma managementLarge university hospitalSeparate biopsiesCirrhosis statusClinical characteristicsClinical suspicionMedian ageEarly diseasePathology databaseRoutine biopsyHCC stageBiopsy resultsHCC patientsParenchymal findingsUniversity HospitalBackground liverHepatocellular carcinomaNontumoral liverHCC biopsiesBiopsyPatientsCirrhosisLiverMedications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol use
2022
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
John BV, Ferreira RD, Doshi A, Kaplan DE, Taddei TH, Spector SA, Paulus E, Deng Y, Bastaich D, Dahman B. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. Journal Of Hepatology 2022, 77: 1349-1358. PMID: 36181987, PMCID: PMC9519143, DOI: 10.1016/j.jhep.2022.07.036.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesCritical COVID-19COVID-19-related deathsThird doseMRNA vaccinesCOVID-19Propensity-matched control groupRetrospective cohort studyModerate COVID-19Symptomatic COVID-19Veterans Health AdministrationBNT-162b2BNT162b2 mRNAModerna mRNACohort studyImmune dysregulationCirrhosisSimilar riskGeneral populationMagnitude of reductionPatientsControl groupHealth AdministrationVaccineAbstractTextCOVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis
John B, Bastaich D, Ferreira R, Doshi A, Taddei T, Kaplan D, Spector S, Deng Y, Dahman B. COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis. Gut 2022, 72: 1800-1802. PMID: 36562753, DOI: 10.1136/gutjnl-2022-327799.Peer-Reviewed Original ResearchComparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis
John BV, Doshi A, Ferreira RD, Taddei TH, Kaplan DE, Spector SA, Deng Y, Bastaich D, Dahman B. Comparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis. Hepatology 2022, 77: 186-196. PMID: 35712794, DOI: 10.1002/hep.32619.Peer-Reviewed Original ResearchConceptsPositive SARS-CoV-2 polymerase chain reactionVaccine-induced immunitySARS-CoV-2 infectionInfection-induced immunityImmunity groupsReduced oddsSARS-CoV-2 polymerase chain reactionCOVID-19Retrospective cohort studyCritical COVID-19Multivariable logistic regressionSARS-CoV-2Unvaccinated participantsUnvaccinated patientsFull vaccinationCohort studyCOVID-19 variantsCommunity prevalencePrevious infectionMRNA vaccinesPolymerase chain reactionUS veteransTreatment weightingCirrhosisPropensity scoreTHU262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis
John B, Doshi A, Deng Y, Mansour N, Barritt A, Moon A, Ioannou G, Martin P, Chao H, Taddei T, Kaplan D, Dahman B. THU262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis. Journal Of Hepatology 2022, 77: s223. PMCID: PMC9252350, DOI: 10.1016/s0168-8278(22)00818-2.Peer-Reviewed Original ResearchPostvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John BV, Deng Y, Schwartz KB, Taddei TH, Kaplan DE, Martin P, Chao H, Dahman B. Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022, 76: 126-138. PMID: 35023206, PMCID: PMC9015228, DOI: 10.1002/hep.32337.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19Breakthrough COVID-19 infectionsBreakthrough COVID-19Propensity-matched cohortRetrospective cohort studyCOVID-19 patientsPfizer BNT162b2Unvaccinated participantsFull vaccinationCohort studyFirst dosePartial vaccinationMultivariable analysisSecond doseUS veteransCirrhosisReduced riskVaccine availabilityPatientsVaccinationVaccineInfectionMortalityDoseEffectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis
John BV, Barritt A, Moon A, Taddei TH, Kaplan DE, Dahman B, , Doshi A, Deng Y, Mansour N, Ioannou G, Martin P, Chao H. Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastroenterology And Hepatology 2022, 20: 2405-2408.e3. PMID: 35716904, PMCID: PMC9212810, DOI: 10.1016/j.cgh.2022.05.038.Peer-Reviewed Original ResearchReply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?”
Torgersen J, Taddei TH, Lo Re V. Reply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?”. Journal Of Hepatology 2022, 77: 258-259. PMID: 35283213, DOI: 10.1016/j.jhep.2022.02.025.Peer-Reviewed Original ResearchStatin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort
Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal Of Hepatology 2022, 76: 1100-1108. PMID: 35066085, PMCID: PMC9018495, DOI: 10.1016/j.jhep.2021.12.034.Peer-Reviewed Original ResearchConceptsChronic liver failureStatin exposureLiver failureStatin useCohort studyChronic liver failure developmentInverse probability treatment weightingProportional hazards regression modelsDoses of statinsVeterans Affairs cohortRetrospective cohort studyChronic liver diseaseHazards regression modelsLarge national cohortVeterans Health AdministrationNumerous beneficial effectsMarginal structural modelsMedian followStatin therapyLiver diseaseNational cohortACLFTreatment weightingCirrhosisPatients
2021
Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis
John BV, Dahman B, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Levy C. Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis. Liver International 2021, 42: 384-393. PMID: 34614294, PMCID: PMC8810619, DOI: 10.1111/liv.15079.Peer-Reviewed Original ResearchConceptsLiver-related deathAMA-negative PBCPBC cirrhosisHepatocellular carcinomaMale patientsAMA-positive patientsAMA-positive PBCLiver-related outcomesSimilar unadjusted ratesAnti-mitochondrial antibodiesSimilar ratesNumber of patientsVeterans Health AdministrationRate of decompensationDevelopment of deathUDCA responseOverall deathUnadjusted ratesCirrhosis diagnosisCirrhosisLarge cohortDecompensationPatientsHealth AdministrationNatural historyMale Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei T, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021, 74: 879-891. PMID: 33636012, DOI: 10.1002/hep.31776.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisLiver-related deathHepatocellular carcinomaBiliary cholangitisMale sexTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityHigher unadjusted ratesRisk of deathVeterans Health AdministrationProportional hazards modelAssociation of sexImpact of sexPBC cirrhosisMale patientsUnadjusted ratesWorse outcomesTotal bilirubinCirrhosisLarge cohortHigh riskHazards modelTransplantationImpact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Schwartz K, Levy C, Dahman B, Deng Y, Martin P, Taddei TH, Kaplan DE. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology Communications 2021, 5: 1426-1436. PMID: 34430786, PMCID: PMC8369937, DOI: 10.1002/hep4.1720.Peer-Reviewed Original ResearchPrimary biliary cholangitisLiver-related mortalityHepatic decompensationOCA useOCA usersPBC cirrhosisObeticholic acidPropensity score modelBiliary cholangitisScore modelRetrospective cohort studySerious liver injuryTreatment of patientsEffect of treatmentCohort studyPartial respondersLiver injuryMultivariable analysisPotential confoundersC-statisticUS veteransUrsodeoxycholic acidBaseline riskCirrhosisDecompensationImpact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDiabetes mellitusLiver diseaseNon-alcoholic fatty liver diseaseCotransporter 2 inhibitorsChronic liver diseaseFatty liver diseaseVeterans Affairs hospitalIncidence of ascitesAdditional pharmacotherapyTreat analysisElectronic health dataSGLT2 inhibitorsSGLT2i usersSurrogate biomarkerDPP4 inhibitorsMetabolic effectsPatientsCirrhosisPropensity scoreAscitesConfirmatory studiesMetforminUrsodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.Peer-Reviewed Original ResearchConceptsLiver-related deathPrimary biliary cholangitisUDCA responseHepatic decompensationHepatocellular carcinomaUrsodeoxycholic acidUDCA respondersPortal hypertensionPartial respondersBiliary cholangitisTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityRetrospective cohort studyProportional hazards modelPBC cirrhosisCompensated cirrhosisCohort studyMale patientsClinical benefitUnadjusted ratesCirrhosisReduced mortalityDecompensationRace Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis
Mahmud N, Asrani SK, Reese PP, Kaplan DE, Taddei TH, Nadim MK, Serper M. Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis. Digestive Diseases And Sciences 2021, 67: 1399-1408. PMID: 33761091, PMCID: PMC8460692, DOI: 10.1007/s10620-021-06943-1.Peer-Reviewed Original ResearchConceptsAcute kidney injuryBaseline eGFREGFR equationsRace adjustmentAKI eventsCKD-EPIGlomerular filtration rate estimating equationsChronic Kidney Disease Epidemiology CollaborationAcute kidney injury eventsIncident acute kidney injuryRetrospective national cohort studyLower baseline eGFRNational cohort studyHigh rateAscites criteriaKidney injuryLower eGFRCohort studyClinical outcomesBlack raceCirrhosisDrug dosingInjury eventsMuscle massPatients